Gabriella Giancane

List of Publications by Citations

Source: https://exaly.com/author-pdf/8405999/gabriella-giancane-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36 890 13 29 g-index

46 1,222 4.6 avg, IF L-index

#	Paper	IF	Citations
36	EULAR recommendations for the management of familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 644-51	2.4	241
35	Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 635-41	2.4	112
34	Juvenile Idiopathic Arthritis: Diagnosis and Treatment. <i>Rheumatology and Therapy</i> , 2016 , 3, 187-207	4.4	102
33	Clinical outcome measures in juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2016 , 14, 23	3.5	74
32	Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. <i>The Lancet Child and Adolescent Health</i> , 2019 , 3, 255-263	14.5	58
31	Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. <i>Arthritis Research and Therapy</i> , 2018 , 20, 285	5.7	41
30	IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis. <i>Frontiers in Pharmacology</i> , 2016 , 7, 467	5.6	33
29	Temporomandibular Joint Involvement in Association With Quality of Life, Disability, and High Disease Activity in Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2017 , 69, 677-686	4.7	32
28	Update on the pathogenesis and treatment of juvenile idiopathic arthritis. <i>Current Opinion in Rheumatology</i> , 2017 , 29, 523-529	5.3	29
27	Primary Hypertrophic Osteoarthropathy: An Update on Patient Features and Treatment. <i>Journal of Rheumatology</i> , 2015 , 42, 2211-4	4.1	18
26	Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era. <i>Arthritis Research and Therapy</i> , 2019 , 21, 168	5.7	16
25	Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis. <i>Rheumatology</i> , 2020 , 59, 3505-3514	3.9	16
24	Anhidrotic ectodermal dysplasia: a new mutation. <i>Journal of Allergy and Clinical Immunology</i> , 2013 , 132, 1451-3	11.5	13
23	Transient hypogammaglobulinemia of infancy: intravenous immunoglobulin as first line therapy. <i>International Journal of Immunopathology and Pharmacology</i> , 2010 , 23, 349-53	3	12
22	Treatment of juvenile idiopathic arthritis: what wnew?. Current Opinion in Rheumatology, 2019, 31, 428-	435	11
21	Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. <i>Arthritis Research and Therapy</i> , 2020 , 22, 71	5.7	9
20	Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases. Current Rheumatology Reports, 2016, 18, 8	4.9	9

(2012-2015)

19	Temporomandibular joint involvement in Juvenile Idiopathic Arthritis: reliability and validity of a screening protocol for the rheumatologist. <i>Pediatric Rheumatology</i> , 2015 , 13, 15	3.5	9	
18	The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients. <i>Pediatric Rheumatology</i> , 2019 , 17, 24	3.5	8	
17	Swollen knee due to primary synovial chondromatosis in pediatrics: a rare and possibly misdiagnosed condition. <i>Rheumatology International</i> , 2013 , 33, 2183-5	3.6	8	
16	Frequency of radiographic damage and progression in individual joints in children with juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2014 , 66, 27-33	4.7	7	
15	Recent therapeutic advances in juvenile idiopathic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017 , 31, 476-487	5.3	6	
14	Evidence based recommendations for genetic diagnosis of Familial Mediterranean Fever. <i>Pediatric Rheumatology</i> , 2014 , 12,	3.5	5	
13	Paediatric rheumatic disease: What is the best definition of clinical remission in JIA?. <i>Nature Reviews Rheumatology</i> , 2017 , 13, 460-461	8.1	3	
12	Agreement among musculoskeletal pediatric specialists in the assessment of radiographic joint damage in juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2014 , 66, 34-9	4.7	3	
11	Growth and Puberty in Juvenile Dermatomyositis: A Longitudinal Cohort Study. <i>Arthritis Care and Research</i> , 2020 , 72, 265-273	4.7	3	
10	A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2019 , 17, 50	3.5	2	
9	Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials. <i>Arthritis Research and Therapy</i> , 2020 , 22, 211	5.7	2	
8	Outcome Scores in Pediatric Rheumatology. Current Rheumatology Reports, 2021, 23, 23	4.9	2	
7	Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries. <i>Rheumatology</i> , 2021 ,	3.9	2	
6	Anakinra in patients with systemic juvenile idiopathic arthritis: long-term safety from the Pharmachild registry <i>Journal of Rheumatology</i> , 2022 ,	4.1	1	
5	The Effect of Morning Stiffness Duration on the Definition of Clinically Inactive Disease in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2020 , 47, 1238-1241	4.1	1	
4	A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2021 , 60, 2896-2905	3.9	1	
3	Determinants of Discordance Between Criteria for Inactive Disease and Low Disease Activity in Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2021 , 73, 1722-1729	4.7	0	
2	Dalle immunodeficienze alle malattie reumatologiche. <i>Area Pediatrica</i> , 2012 , 13, 72-76			

Dalle immunodeficienze alle malattie reumatologiche. *Area Pediatrica*, **2012**, 13, 111-116